Related Experiment Video

Updated: May 3, 2026

Implementation of In Vitro Drug Resistance Assays: Maximizing the Potential for Uncovering Clinically Relevant Resistance Mechanisms
08:46

Implementation of In Vitro Drug Resistance Assays: Maximizing the Potential for Uncovering Clinically Relevant Resistance Mechanisms

Published on: December 9, 2015

10.5K

Elucidating the Mechanisms of Acquired Palbociclib Resistance via Comprehensive Metabolomics Profiling

Lulu Yang1, Yajun Yue2, Zhendong Wang3

  • 1Technology Innovation Center of Mass Spectrometry for State Market Regulation, Center for Advanced Measurement Science, National Institute of Metrology, Beijing 100029, China.

Current Issues in Molecular Biology
|January 24, 2025
PubMed

Insights

This study investigated palbociclib resistance in colorectal cancer cells. Researchers found 76 metabolite differences, revealing potential metabolic mechanisms driving drug resistance.

Area of Science:

  • Oncology
  • Metabolomics
  • Cancer Biology

Background:

  • Palbociclib is a cyclin-dependent kinase 4/6 inhibitor used in cancer therapy.
  • Mechanisms of palbociclib resistance, particularly metabolic alterations, remain largely unknown.
  • Colorectal cancer (CRC) is a significant area of oncology research.

Purpose of the Study:

  • To investigate the metabolic changes associated with palbociclib resistance in colorectal cancer cells.
  • To identify specific metabolites and pathways affected by palbociclib resistance.
  • To elucidate the role of metabolism in the development of anti-palbociclib resistance.

Main Methods:

  • Utilized liquid chromatography-mass spectrometry (LC-MS) based metabolomics.
  • Analyzed metabolite expression differences in palbociclib-resistant SW620 cells compared to parental SW620 cells.
  • Employed MetaboAnalyst 6.0 for metabolic pathway analysis.

Main Results:

  • Identified 76 distinct metabolite expression differences between resistant and parental SW620 cells.
  • Observed alterations in amino acid metabolism, glutathione pathways, and ABC transporter expression.
  • Disruptions were noted in arginine synthesis, beta-alanine metabolism, and purine metabolism pathways.

Conclusions:

  • Metabolic reprogramming, including amino acid and purine metabolism, is implicated in palbociclib resistance.
  • These findings offer potential insights into the metabolic underpinnings of cancer drug resistance.
  • The study provides a foundation for further research into overcoming anti-palbociclib resistance.
Keywords:
LC-MSSW620 cellscancer biologydrug resistancemetabolomics

More Related Videos

Systems Biology of Metabolic Regulation by Estrogen Receptor Signaling in Breast Cancer10:36

Systems Biology of Metabolic Regulation by Estrogen Receptor Signaling in Breast Cancer

Published on: March 17, 2016

10.4K
Looking for Driver Pathways of Acquired Resistance to Targeted Therapy: Drug Resistant Subclone Generation and Sensitivity Restoring by Gene Knock-down08:59

Looking for Driver Pathways of Acquired Resistance to Targeted Therapy: Drug Resistant Subclone Generation and Sensitivity Restoring by Gene Knock-down

Published on: December 11, 2017

7.2K

Related Concept Videos

Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
2.6K
Pharmacogenetics of Drug Metabolism: Overview01:27

Pharmacogenetics of Drug Metabolism: Overview

Genetic polymorphism in drug metabolism is crucial to the inter-individual variability observed in drug responses. Drug metabolism primarily involves the chemical modification of drugs and other xenobiotics to enhance their elimination by increasing their polarity. Two main classes of enzymes mediate this biotransformation process: Phase I enzymes, primarily cytochrome P450s, catalyze oxidation and reduction reactions, while other enzymes, such as esterases, mediate hydrolysis, and Phase II...
194
Pharmacogenomics: Identification of New Drug Targets01:29

Pharmacogenomics: Identification of New Drug Targets

Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
121